Body & Peptide Science · System 07

Skin & Hair

How GHK-Cu, Melanotan II, and KPV are described in the literature to interact with collagen remodeling, melanocortin pigment pathways, and skin inflammation.

3 compounds studied9 primary sourcesResearch use only

The system at a glance

The skin is a layered organ: a keratinocyte-rich epidermis over a fibroblast-driven dermis of collagen and elastin, with resident melanocytes that make pigment and follicles that grow hair. Three signaling themes dominate the peptide literature here. First, the copper tripeptide GHK-Cu is studied for its influence on the dermal extracellular matrix, where it associates with fibroblast activity, collagen and matrix-protein synthesis, and remodeling after injury. Second, the melanocortin system, in which alpha-MSH-like signaling through the melanocortin-1 receptor (MC1R) on melanocytes drives melanogenesis, is the axis engaged by the synthetic analog Melanotan II. Third, anti-inflammatory melanocortin signaling, captured by the C-terminal fragment KPV, is examined in models of skin and mucosal inflammation independent of pigment. This page describes the documented mechanisms and what was actually studied, not how anything is used.

How it signals

GHK-Cu has the strongest human footprint of the three, with cultured human dermal fibroblast work plus references to controlled cosmetic-skin studies, though the highest-quality human data is small and industry-linked. Melanotan II’s biology (MC1R-driven melanogenesis) is understood, but its human record is largely uncontrolled real-world use and adverse-event/case reports rather than trials. KPV’s anti-inflammatory activity is documented mostly in vitro and in animal models. Evidence tiers below reflect this: mechanism can be well characterized while controlled human skin outcomes remain thin.

Research peptides studied in this system

Each card summarizes the documented mechanism, what was actually studied and in what model, and how strong the evidence is. These are descriptions of laboratory research — not recommendations, and not evidence of benefit in humans. According to research indexed in PubMed:

GHK-Cucopper tripeptide; glycyl-L-histidyl-L-lysine copper(II) complexModerate mechanistic + limited human cosmetic-skin data

Documented mechanism

GHK is a human tripeptide (Gly-His-Lys) with a copper-binding affinity resembling the copper-transport site on albumin, forming the GHK-Cu complex. In the reviewed literature it is associated with dermal tissue remodeling: chemoattraction of repair cells, anti-inflammatory and antioxidant actions, and increased fibroblast synthesis of matrix proteins including collagen, elastin, and metalloproteinases alongside growth factors. In cultured human dermal fibroblasts it has also been reported to modulate IGF-2-dependent TGF-beta1 secretion, a pathway relevant to scar and matrix formation. ¹²³

What was actually studied

Reviewed across cell-culture (normal human dermal fibroblasts, keratinocytes) and animal wound-healing models; the source review also cites controlled studies on aged human skin reporting tightening, elasticity, and reduced fine lines/photodamage. Recent work embeds GHK-Cu in wound-dressing hydrogels tested in infection/wound models.

Evidence tier

Human cosmetic-skin outcomes exist but the higher-quality controlled data are small and partly industry-associated; much mechanistic detail comes from in-vitro and animal work. This describes documented biology, not any use, dose, or regimen.

Melanotan IIMT-II; synthetic cyclic alpha-MSH analogLow-quality human data (mechanism clear; human record largely uncontrolled)

Documented mechanism

Melanotan II is a synthetic cyclic analog of alpha-melanocyte-stimulating hormone (alpha-MSH). The underlying pathway is melanocortin signaling: alpha-MSH-type ligands activate the melanocortin-1 receptor (MC1R) on melanocytes, raising cAMP and driving melanogenesis (eumelanin production) and melanocyte dendricity. Melanotan II is a broad melanocortin-receptor agonist, which is why its documented effects extend beyond pigment. ⁴⁵⁶⁷⁹

What was actually studied

The melanocortin/MC1R melanogenesis mechanism is characterized in human keratinocyte and melanocyte studies. Human information on Melanotan II itself is dominated by real-world, unregulated internet-sourced use documented in case studies and adverse-event reports rather than controlled trials.

Evidence tier

Honest limit: human Melanotan II data are largely uncontrolled. Published reports include systemic toxicity with rhabdomyolysis after injection and cases of melanoma temporally associated with use; product identity and purity in these reports are variable. Described here at the mechanism level only, with no tanning or cosmetic framing.

KPVLys-Pro-Val; alpha-MSH(11-13) C-terminal tripeptideLow-quality clinical data (in-vitro/animal anti-inflammatory mechanism)

Documented mechanism

KPV is the C-terminal tripeptide of alpha-MSH. Notably it is reported to lack the classical melanocortin-receptor binding motif (though some studies report residual MC1R binding), yet retains much of alpha-MSH’s anti-inflammatory activity while displaying no pigmentary action. Documented effects include dampening NF-kappaB activation, reducing pro-inflammatory cytokine and adhesion-molecule expression, and modulating antigen-presenting-cell and T-cell activity, positioning it as a barrier/anti-inflammatory signaling peptide distinct from the pigment axis. ⁸⁷

What was actually studied

Characterized primarily in vitro and in animal models of skin and mucosal inflammation, including contact hypersensitivity/dermatitis and related immune-mediated models; reviewed as a candidate anti-inflammatory peptide. Human skin trial data are minimal.

Evidence tier

Its exact receptor/signaling route is not fully resolved and controlled human skin data are lacking; anti-inflammatory activity here is a research-model observation, not an established skin therapy. No dose, timing, or protocol implied.

What we don’t know — and the risks

Honest limits matter as much as the mechanisms. For this system specifically:

Research-use-only context: none of these compounds is presented here as a treatment; mechanisms are drawn from cell, animal, and limited human studies, not from clinical guidance.
Melanotan II carries documented human harms in the literature, including systemic sympathomimetic toxicity with rhabdomyolysis and renal dysfunction after injection, and melanoma reported in temporal association with use; unregulated products vary in identity and purity.
Broad melanocortin agonism means effects are not limited to skin, and melanocytic/mole changes reported alongside pigment-directed melanocortin use warrant caution in any research interpretation.
GHK-Cu’s strongest human cosmetic-skin claims come from small and partly industry-linked studies; much of the mechanistic picture is in-vitro or animal and should not be over-read as proven clinical benefit.
KPV’s anti-inflammatory profile is largely preclinical (in-vitro and animal models); its human skin efficacy and its precise molecular target are not established.
Injectable, unregulated peptides raise general research-handling concerns (sterility, contamination, mis-identification) that are independent of any biological mechanism described above.

Responsible understanding

◆ This is education, not medical advice

This page is educational and describes what has been studied in laboratory and clinical research. It is not medical advice, and these materials are for research use only — not for human or veterinary use. Timing, administration, and whether anything is used at all are clinical decisions that belong with a licensed physician overseeing your care; we take no position on them. Science and regulation evolve; verify anything important against the primary sources below.

Sources

Based on articles retrieved from PubMed. Follow each link to the original paper.

Pickart L The human tri-peptide GHK and tissue remodeling Journal of Biomaterials Science, Polymer Edition. 2008;J Biomater Sci Polym Ed. 2008;19(8):969-88. DOI
Chen H, Yang P, Xue P, Li S, Dan X, Li Y, Lei L, Fan X Food-Derived Tripeptide-Copper Self-Healing Hydrogel for Infected Wound Healing Biomaterials Research. 2025;Biomater Res. 2025;29:0139. DOI
Gruchlik A, Chodurek E, Dzierzewicz Z Effect of Gly-His-Lys and its copper complex on TGF-beta secretion in normal human dermal fibroblasts Acta Poloniae Pharmaceutica. 2014;Acta Pol Pharm. 2014;71(6):954-8. PubMed
Van Hout MC, Brennan R An in-depth case examination of an exotic dancer’s experience of melanotan International Journal on Drug Policy. 2013;Int J Drug Policy. 2013;25(3):444-50. DOI
Nelson ME, Bryant SM, Aks SE Melanotan II injection resulting in systemic toxicity and rhabdomyolysis Clinical Toxicology (Philadelphia). 2012;Clin Toxicol (Phila). 2012;50(10):1169-73. DOI
Paurobally D, Jason F, Dezfoulian B, Nikkels AF Melanotan-associated melanoma British Journal of Dermatology. 2011;Br J Dermatol. 2011;164(6):1403-5. DOI
Brzoska T, Bohm M, Lugering A, Loser K, Luger TA Terminal signal: anti-inflammatory effects of alpha-melanocyte-stimulating hormone related peptides beyond the pharmacophore Advances in Experimental Medicine and Biology. 2010;Adv Exp Med Biol. 2010;681:107-16. DOI
Luger TA, Scholzen TE, Brzoska T, Bohm M New insights into the functions of alpha-MSH and related peptides in the immune system Annals of the New York Academy of Sciences. 2003;Ann N Y Acad Sci. 2003;994:133-40. DOI
Rousseau K, Kauser S, Pritchard LE, Warhurst A, Oliver RL, Slominski A, Wei ET, Thody AJ, Tobin DJ, White A Proopiomelanocortin (POMC), the ACTH/melanocortin precursor, is secreted by human epidermal keratinocytes and melanocytes and stimulates melanogenesis FASEB Journal. 2007;FASEB J. 2007;21(8):1844-56. DOI

Body & Peptide Science · Skin & Hair · Draft for review
Research-use-only educational content. Nothing here is medical, dosing, timing, or treatment advice.